In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients

NeuroImmunoModulation

Volumn 13, Issue 2, 2006, Pages 76-81

  Angelucci, Francesco ^a,b   Batocchi, Anna Paola ^a   Caggiula, Marcella ^a,b   Frisullo, Giovanni ^a   Patanella, Katia ^a   Sancricca, Cristina ^a   Nociti, Viviana ^a   Tonali, Pietro Attilio ^a,b   Mirabella, Massimiliano ^a,c  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cytokines; Interleukin 10; Interleukin 6; Mitoxantrone; Multiple sclerosis; Peripheral blood mononuclear cells

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 6; MITOXANTRONE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; TIME; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; UP-REGULATION;

EID: 33751351302     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095762     Document Type: Article

References (34)

1. Voltz R, Starck M, Zingler V, Strupp M, Kolb HJ: Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler 2004;10:472-474.
2. Kapuscinski J, Darzynkiewicz Z: Condensation of nucleic acids by intercalating aromatic cations. Proc Natl Acad Sci USA 1984;81:7368-7372.
3. Fox ME, Smith PJ: Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 1990;50:813-818.
4. Fidler JM, DeJoy SQ, Smith FR 3rd, Gibbons JJ Jr: Selective immunomodulation by the antineoplastic agent mitoxantrone. 2. Nonspecific adherent suppressor cell derived from mitoxantrone-treated mice. J Immunol 1986;136:2747-2754.
5. Fidler JM, DeJoy SQ, Gibbons JJ Jr: Selective immunomodulation by the antineoplastic agent mitoxantrone. 1. Suppression of B lymphocyte function. J Immunol 1986;137:727-732.
6. Gbadamosi J, Buhmann C, Tessmer W, Moench A, Haag F, Heesen C: Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10. Eur Neurol 2003;49:137-141.
7. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z: The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 1993;53:3186-3192.
8. Gonsette RE, Demonty L: Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990;40(suppl 1):261.
9. Kappos L, Gold R, Künstler E, Rohrbach E, Heun R, Städt D, Hofmann E: Mitoxantrone (MX) in the treatment of rapidly progressive multiple sclerosis: a pilot study with serial gadolinium (GD)-enhanced MRI. Neurology 1990;49(suppl 1):261.
10. Noseworthy JH, Lee D, Penman M, Hopkins M, Vandervoort MK, Karlik SJ, Rice GPA, Grinwich KD, Ebers GC: A phase II evaluation of mitoxantrone HCI in the treatment of progressive multiple sclerosis. Neurology 1991;41(suppl):146.
11. Noseworthy JH, Hopkins MB, Vandervoort MK, Karlik SJ, Lee DH, Penman M, Rice GP, Grinwich KD, Cauvier H, Harris BJ: An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993;43:1401-1406.
12. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H: Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992;242:96-102.
13. Mauch E, Kornhuber HH: Immunosuppressive therapy of multiple sclerosis with mitoxantrone. Fortschr Neurol Psychiatry 1993;61:410-417.
14. Krapf H, Mauch E, Fetzer U, Laufen H, Kornhuber HH: Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995;37:113-119.
15. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraud O: Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
16. Bastianello S, Pozzilli C, D'Andrea F, Millefiorini E, Trojano M, Morino S, Gasperini C, Bozzao A, Gallucci M, Andreula C, Bozzao L, Gambi D, Prencipe M: A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 1994;21:266-270.
17. Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, Morino S, Morra VB, Bozzao A, Calo A, Bernini ML, Gambi D, Prencipe M: Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
18. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T, Mitoxantrone in Multiple Sclerosis Study Group (MIMS): Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025.
19. Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP, MIMS Study Group: Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005;65:690-695.
20. Jeffery DR, Herndon R: Review of mitoxantrone in the treatment of multiple sclerosis. Neurology 2004;63(suppl 6):S19-S24.
21. Chan A, Weilbach FX, Toyka KV, Gold R: Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005;139:152-158.
22. Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stuve O, Hartung HP: Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005;168:128-137.
23. Martino G, Furlan R, Brambilla E, Bergami A, Ruffini F, Gironi M, Poliani PL, Grimaldi LM, Comi G: Cytokines and immunity in multiple sclerosis: the dual signal hypothesis. J Neuroimmunol 2000;109:3-9.
24. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
25. Van Boxel-Dezaire AH, Hoff SC, van Oosten BW, Verweij CL, Drager AM, Ader HJ, van Houwelingen JC, Barkhof F, Polman CH, Nagelkerken L: Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999;45:695-703.
26. Reinhold D, Perlov E, Schrecke K, Kekow J, Brune T, Sailer M: Increased blood plasma concentrations of TGF-beta isoforms after treatment with intravenous immunoglobulins (ivIG) in patients with multiple sclerosis. J Neuroimmunol 2004;152:191-194.
27. Fox EJ: Mechanism of action of mitoxantrone. Neurology 2004;63(suppl 6):S15-S18.
28. Gadient RA, Otten UH: Interleukin-6 (IL-6) - A molecule with both beneficial and destructive potentials. Prog Neurobiol 1997;52:379-390.
29. Ishihara K, Hirano T: IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357-368.
30. Okuda Y, Sakoda S, Fujimura H, Saeki Y, Kishimoto T, Yanagihara T: IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis. J Neuroimmunol 1999;101:188-196.
31. Okuda Y, Sakoda S, Saeki Y, Kishimoto T, Yanagihara T: Enhancement of Th2 response in IL-6-deficient mice immunized with myelin oligodendrocyte glycoprotein. J Neuroimmunol 2000;105:120-123.
32. Beebe AM, Cua DJ, de Waal Malefyt R: The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev 2002;13:403-412.
33. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR: Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J Neuroimmunol 2004;146:209-215.
34. Kipnis J, Avidan H, Caspi RR, Schwartz M: Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia. Proc Natl Acad Sci USA 2004;101:14663-14669.